Virginia Hemp Restrictions: Laws, Regulations, and Industry Impact

Executive Summary

Virginia's sweeping hemp restrictions took effect in August 2026 after a federal judge declined to issue a preliminary injunction blocking the law, fundamentally reshaping the Commonwealth's legal cannabis marketplace. The new regulations impose strict limits on hemp-derived intoxicating cannabinoids, including delta-8 THC, THCA, and other psychoactive compounds that had flourished in a regulatory gray zone since the 2018 Farm Bill federally legalized hemp. The law establishes a state-controlled licensing system, bans sales to individuals under 21, mandates child-resistant packaging, and restricts product potency and serving sizes. Industry stakeholders—ranging from small hemp retailers to multi-state operators positioning for Virginia's eventual adult-use cannabis market—face immediate compliance deadlines, potential criminal penalties, and market consolidation. The judicial decision represents a critical inflection point in the national debate over hemp-derived intoxicants, with Virginia joining a growing number of states attempting to close what regulators describe as dangerous loopholes while hemp advocates characterize the measures as regulatory overreach that threatens a legitimate agricultural industry.

Why This Matters

Virginia's hemp restrictions affect thousands of retailers, hundreds of manufacturers, and an estimated market worth $150-200 million annually in the Commonwealth alone. The policy shift impacts multiple stakeholder groups with competing interests and significant financial exposure.

For consumers, the restrictions eliminate access to products previously available at gas stations, convenience stores, and specialty hemp shops. An estimated 300,000 Virginia residents purchased hemp-derived cannabinoid products in 2025, according to industry surveys. Many used these products as alternatives to pharmaceutical medications for anxiety, chronic pain, and sleep disorders, often citing lower costs and greater accessibility compared to the state's limited medical cannabis program.

Small business owners face existential threats. Virginia had approximately 1,200 licensed hemp retailers as of July 2026, with many operating on thin margins. The new licensing requirements, compliance costs, and product restrictions force immediate business model changes. Retailers must invest in new point-of-sale systems, employee training, inventory management, and legal compliance—expenses that industry groups estimate at $15,000-50,000 per location.

Multi-state operators and vertically integrated cannabis companies view Virginia's restrictions through a different lens. By creating a more tightly regulated hemp market, the law potentially reduces competition ahead of the state's planned adult-use cannabis launch, currently scheduled for 2027. Companies like Green Leaf Medical and Columbia Care Virginia have invested tens of millions in cultivation and processing infrastructure, expecting regulatory frameworks that favor licensed operators over unregulated hemp sellers.

Public health officials and law enforcement supported the restrictions, citing concerns about product safety, youth access, and impaired driving. The Virginia Department of Health documented 127 emergency room visits in 2025 involving hemp-derived cannabinoid products, including cases of severe intoxication in minors who consumed high-potency edibles. State police reported difficulties distinguishing legal hemp products from illegal cannabis during traffic stops, complicating enforcement of DUI laws.

Background and History

Virginia's hemp restrictions emerged from a complex interplay of federal policy changes, state legislative responses, and rapid market evolution that began with the 2018 Farm Bill.

The 2018 Farm Bill and Hemp Legalization

The federal Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp—defined as cannabis containing no more than 0.3% delta-9 THC by dry weight—from Schedule I of the Controlled Substances Act. This single provision, championed by Senate Majority Leader Mitch McConnell, created a legal pathway for hemp cultivation, processing, and sales nationwide. The law explicitly preserved state authority to regulate hemp within their borders, setting the stage for a patchwork of state-level approaches.

Virginia responded quickly. The General Assembly passed House Bill 1839 in the 2019 legislative session, establishing a state hemp program administered by the Virginia Department of Agriculture and Consumer Services. Governor Ralph Northam signed the measure on March 22, 2019. The law created a licensing framework for hemp cultivation and processing, aligning Virginia with USDA guidelines while imposing minimal restrictions on finished hemp products sold to consumers.

The Rise of Intoxicating Hemp Derivatives

Between 2019 and 2021, a new category of hemp-derived products emerged that would ultimately trigger Virginia's restrictive response. Manufacturers discovered they could extract and concentrate minor cannabinoids from legal hemp, creating intoxicating products that technically complied with the 0.3% delta-9 THC threshold while delivering psychoactive effects comparable to traditional cannabis.

Delta-8 THC, a naturally occurring cannabinoid present in trace amounts in hemp, became the first breakout product. Through chemical conversion processes using CBD isolate, manufacturers produced delta-8 THC in concentrated forms for vaping, edibles, and tinctures. The compound produces euphoria and intoxication similar to delta-9 THC but remained legal under a literal reading of the Farm Bill's definition of hemp.

Virginia's first delta-8 THC retailers appeared in Richmond and Virginia Beach in late 2020. By mid-2021, the products were available in hundreds of locations statewide, including gas stations, smoke shops, and dedicated hemp boutiques. No age restrictions, labeling requirements, or potency limits applied to these products under existing Virginia law.

THCA: The Next Wave

As some states moved to ban delta-8 THC in 2021 and 2022, the hemp industry pivoted to THCA—tetrahydrocannabinolic acid, the non-intoxicating precursor to delta-9 THC found in raw cannabis. When heated through smoking or vaping, THCA converts to psychoactive delta-9 THC. Because THCA itself is not delta-9 THC, hemp flower containing high levels of THCA but less than 0.3% delta-9 THC in its raw form technically qualified as legal hemp under federal and Virginia law.

THCA flower products exploded across Virginia in 2023 and 2024. Retailers sold pre-rolled joints, smokable flower, and vape cartridges containing THCA-rich hemp that, when consumed, delivered effects indistinguishable from traditional marijuana. The products often featured strain names like Northern Lights, OG Kush, and Wedding Cake—cultivars developed for high-THC cannabis markets. Prices undercut Virginia's limited medical cannabis dispensaries, and no medical card was required for purchase.

Legislative Attempts and Political Dynamics

Virginia lawmakers first attempted to address intoxicating hemp products in the 2022 General Assembly session. Delegate Michael Cherry introduced House Bill 933, which would have banned delta-8 THC and established testing requirements for hemp products. The bill died in committee after hemp industry lobbyists argued it would devastate Virginia's emerging agricultural sector and eliminate jobs in rural communities.

The 2023 session saw renewed efforts. Senate Bill 1464, sponsored by Senator Siobhan Dunnavant, proposed age restrictions and labeling requirements for hemp-derived cannabinoids. The measure passed the Senate 28-12 but stalled in the House Agriculture Committee amid disagreements over enforcement mechanisms and concerns about federal preemption.

Political dynamics shifted in late 2023 when Governor Glenn Youngkin, previously focused on limiting adult-use cannabis expansion, identified intoxicating hemp products as a priority issue. In a November 2023 speech to the Virginia Association of Chiefs of Police, Youngkin described the hemp market as "an end-run around our state's careful approach to cannabis policy" and pledged to work with legislators on comprehensive restrictions.

The 2024 Legislative Session and HB 698

The breakthrough came in the 2024 General Assembly session. Delegate Terry Austin introduced House Bill 698 in January 2024, backed by a coalition including the Virginia Department of Health, the Virginia Retail Federation, and licensed medical cannabis operators. The bill proposed comprehensive restrictions on hemp-derived intoxicating products, including licensing requirements, age limits, potency caps, and child-resistant packaging mandates.

The House of Delegates passed HB 698 on February 14, 2024, by a vote of 67-32. The Senate approved an amended version on March 8, 2024, with a 24-16 vote. A conference committee reconciled differences, and both chambers approved the final version on March 20, 2024. Governor Youngkin signed the bill into law on April 3, 2024, with an effective date of July 1, 2026—a delayed implementation designed to give businesses time to comply.

Legal Challenges and the Path to Implementation

Within weeks of the governor's signature, the Virginia Hemp Coalition—a trade association representing approximately 400 hemp businesses—announced plans to challenge the law. On June 15, 2024, the coalition filed suit in the U.S. District Court for the Eastern District of Virginia, arguing that HB 698 violated the Commerce Clause, conflicted with federal hemp law, and imposed unconstitutionally vague standards.

The case, Virginia Hemp Coalition v. Miyares, proceeded through discovery and motion practice over two years. On July 22, 2026, just days before the law's scheduled effective date, U.S. District Judge Anthony Trenga heard arguments on the coalition's motion for a preliminary injunction. The hemp industry presented testimony from small business owners facing closure, economists projecting job losses, and legal experts arguing federal preemption.

The Commonwealth's attorneys, led by Virginia Attorney General Jason Miyares, countered with public health data, testimony from emergency room physicians, and legal arguments emphasizing states' traditional police powers to regulate intoxicating substances. On August 10, 2026, Judge Trenga issued a 47-page opinion denying the preliminary injunction, finding that Virginia had demonstrated a compelling state interest in regulating intoxicating products and that the hemp coalition had not shown a likelihood of success on the merits of their federal preemption claims.

The law took effect as scheduled on August 15, 2026, immediately transforming Virginia's hemp marketplace.

Key Players

Virginia Department of Agriculture and Consumer Services

VDACS administers Virginia's hemp program and oversees licensing for hemp retailers under the new restrictions. The agency established an expedited application process for existing hemp businesses seeking compliance licenses, with a 60-day window from the law's effective date. Commissioner Joseph Guthrie stated in July 2026 that VDACS had hired 12 additional inspectors and compliance officers to handle enforcement responsibilities. The agency faces the challenge of transitioning from a permissive agricultural oversight role to active marketplace regulation with criminal penalties for violations.

Virginia Cannabis Control Authority

The CCA, established in 2021 to oversee Virginia's medical and future adult-use cannabis programs, gained new authority under HB 698 to coordinate with VDACS on hemp product testing standards and laboratory certification. Executive Director Aaron Bowles described the hemp restrictions as "creating regulatory alignment" between hemp and cannabis markets, potentially simplifying the transition to adult-use sales. The CCA's involvement signals Virginia's intent to eventually merge hemp and cannabis regulatory frameworks.

Virginia Hemp Coalition

This trade association, formed in 2022, represents hemp farmers, processors, retailers, and ancillary businesses. The coalition raised approximately $800,000 for its legal challenge to HB 698, according to financial disclosures filed in federal court. Executive Director Marcus Williams characterized the restrictions as "prohibitionist policies disguised as consumer protection" and vowed to continue litigation despite the preliminary injunction denial. The coalition's membership reportedly declined from 400 businesses in 2024 to fewer than 250 by August 2026 as companies exited the market or ceased dues payments.

Licensed Medical Cannabis Operators

Virginia's five vertically integrated pharmaceutical processors—gLeaf Medical Virginia, Columbia Care, Dharma Pharmaceuticals, Green Leaf Medical, and Dalitso—publicly supported HB 698. These companies invested over $200 million combined in cultivation facilities, processing labs, and dispensaries under Virginia's medical cannabis program, which launched in 2020. They argued that unregulated hemp products undermined their compliance costs and created unfair competition. Green Leaf Medical CEO Michael Bronfein stated in February 2024 testimony that "patients deserve the same safety standards whether they purchase from a licensed dispensary or a gas station."

Governor Glenn Youngkin

The Republican governor, elected in 2021, positioned hemp restrictions as consistent with his broader cannabis policy approach emphasizing regulation and public safety over market expansion. Youngkin opposed efforts to accelerate adult-use cannabis sales in Virginia, arguing the state should "get medical cannabis right first." His support for HB 698 aligned with law enforcement constituencies while allowing him to claim action on cannabis policy without embracing broader legalization. The governor's office issued a statement on August 15, 2026, praising the law's implementation as "protecting Virginia families while supporting legitimate hemp agriculture."

Delegate Terry Austin

The Republican delegate from Botetourt County served as HB 698's chief patron. Austin, a pharmacist by profession, framed the legislation as a consumer protection measure rather than prohibition. In floor speeches, he emphasized product safety, accurate labeling, and preventing youth access. Austin received campaign contributions totaling $18,500 from licensed cannabis operators and pharmaceutical companies between 2023 and 2025, according to Virginia Public Access Project records, though he stated these donations did not influence his legislative priorities.

Legal and Regulatory Framework

Virginia's hemp restrictions rest on a complex statutory foundation that amends multiple sections of the Code of Virginia while navigating federal hemp law and constitutional constraints.

Federal Framework: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition removed hemp from the Controlled Substances Act, 21 U.S.C. § 812, making it an agricultural commodity rather than a controlled substance.

Critically, Section 1639o(a)(2) preserves state authority: "Nothing in this section prohibits the State from adopting laws or regulations governing the production of hemp that are more stringent than this section." This savings clause provided Virginia's legal foundation for imposing restrictions beyond federal requirements.

Virginia Code Amendments

HB 698 amended Virginia Code § 3.2-4112 through § 3.2-4123, creating a new regulatory structure for "hemp-derived intoxicating products." The law defines this category as "any product containing more than 2 milligrams of total THC per package or more than 0.3 milligrams of total THC per serving, derived from hemp as defined by federal law."

Key statutory provisions include:

Licensing Requirements (§ 3.2-4115): Any person selling hemp-derived intoxicating products must obtain a Hemp Retail License from VDACS. Application fees are set at $500 annually, with background checks required for all owners and managers. Licenses may be denied for prior drug felony convictions within 10 years or any conviction involving sales to minors.

Age Restrictions (§ 3.2-4116): Sales to persons under 21 are prohibited, with criminal penalties including up to 12 months imprisonment and $2,500 fines for violations. Retailers must verify age through government-issued identification for any customer appearing under 30 years old. The statute creates an affirmative defense if the retailer checked identification showing the purchaser was 21 or older, even if the ID was fraudulent.

Product Standards (§ 3.2-4117): Hemp-derived intoxicating products must not exceed 2 milligrams total THC per serving or 10 milligrams total THC per package for edibles. Smokable hemp flower is capped at 0.3% total THC by dry weight. Products must undergo testing by VDACS-certified laboratories for potency, pesticides, heavy metals, and microbial contaminants. Results must be available to consumers via QR code or printed certificate of analysis.

Packaging and Labeling (§ 3.2-4118): All products require child-resistant packaging meeting standards established in 16 C.F.R. § 1700.20. Labels must include total THC content, serving size, a warning statement that the product is intoxicating, and a prohibition on use during pregnancy. Products cannot use cartoon characters, bright colors, or other designs appealing to minors. Brand names cannot include terms like "candy," "cookie," or other words associated with products marketed to children.

Prohibited Locations (§ 3.2-4119): Sales are banned within 500 feet of schools, playgrounds, and childcare facilities, measured from property line to property line. This provision forced closure of an estimated 150-200 existing hemp retailers in Virginia based on location alone.

Enforcement and Penalties

Virginia Code § 3.2-4121 establishes a tiered penalty structure. First violations of licensing or age verification requirements are Class 1 misdemeanors, punishable by up to 12 months in jail and $2,500 fines. Second violations within 36 months are Class 6 felonies, carrying 1-5 years imprisonment. Sales to minors carry enhanced penalties, including mandatory license revocation.

VDACS inspectors have authority to conduct unannounced inspections, seize non-compliant products, and issue administrative citations with civil penalties up to $10,000 per violation. The statute creates a private right of action for parents whose children purchase hemp products in violation of the law, allowing recovery of actual damages plus $5,000 statutory damages per violation.

Constitutional and Preemption Questions

The Virginia Hemp Coalition's lawsuit raised three primary legal challenges. First, the coalition argued that HB 698's restrictions on interstate commerce in hemp products violated the dormant Commerce Clause, U.S. Const. art. I, § 8, cl. 3, by discriminating against out-of-state manufacturers who could not economically reformulate products for Virginia's unique standards.

Second, the coalition claimed federal preemption under the Supremacy Clause, U.S. Const. art. VI, cl. 2, arguing that the 2018 Farm Bill established a comprehensive federal framework for hemp that precluded state restrictions on products meeting the federal definition. The coalition cited the Farm Bill's explicit legalization of "all derivatives, extracts, cannabinoids" from hemp as evidence of congressional intent to preempt state prohibitions.

Third, the coalition asserted that the law's definition of "intoxicating" products was unconstitutionally vague, failing to provide fair notice of prohibited conduct in violation of the Due Process Clause of the Fourteenth Amendment.

In his August 10, 2026 opinion denying preliminary injunctive relief, Judge Trenga rejected each argument. On Commerce Clause grounds, he found that Virginia's restrictions applied equally to in-state and out-of-state manufacturers and served legitimate local purposes of protecting public health and safety. On preemption, Trenga emphasized the Farm Bill's explicit preservation of state regulatory authority in 7 U.S.C. § 1639o(a)(2), finding no evidence of congressional intent to occupy the field. On vagueness, the court held that the statute's quantitative THC thresholds provided sufficient clarity for ordinary persons to understand prohibited conduct.

The case remains pending on the merits, with trial scheduled for March 2027.

Market and Business Implications

Virginia's hemp restrictions triggered immediate market consolidation, with industry analysts projecting 40-60% of existing retailers will exit the market by the end of 2026.

Retail Sector Disruption

The licensing requirements, location restrictions, and compliance costs created immediate financial pressure on Virginia's estimated 1,200 hemp retailers. Small independent shops operating on margins of 15-20% faced compliance expenses that industry consultants estimated at $15,000-50,000 per location, including:

• VDACS licensing fees: $500 annually
• Point-of-sale system upgrades for age verification: $2,000-5,000
• Inventory replacement for non-compliant products: $10,000-30,000
• New packaging and labeling: $3,000-8,000
• Legal and consulting fees: $5,000-15,000
• Employee training programs: $1,000-3,000

Convenience stores and gas stations, which accounted for approximately 40% of hemp product sales in Virginia, largely exited the market. The compliance burden and liability risks outweighed profit margins on hemp products, which typically generated $2,000-5,000 monthly revenue per location. Major chains including 7-Eleven, Wawa, and Sheetz announced in July 2026 that they would discontinue hemp-derived cannabinoid products in Virginia stores effective August 15.

Dedicated hemp retailers faced different calculations. Shops generating $30,000-100,000 monthly revenue from hemp products could potentially absorb compliance costs, but the 500-foot school buffer zone forced closures for many urban locations. In Richmond, 18 of 47 hemp shops fell within the prohibited zone. Norfolk lost 12 of 31 locations.

Wholesale and Manufacturing Impact

Virginia-based hemp processors and manufacturers confronted product reformulation requirements that threatened existing inventory and supply chains. Products exceeding the 2-milligram-per-serving THC limit—which included most gummies, chocolates, and beverages on the market—required complete reformulation or became unsalable in Virginia.

Manufacturers reported that reformulation costs ranged from $50,000 to $200,000 per product line, including new lab testing, packaging design, and production line modifications. Many companies chose instead to focus on other states with less restrictive frameworks, effectively abandoning the Virginia market.

The wholesale price of THCA hemp flower collapsed in Virginia. Prices fell from $400-600 per pound in June 2026 to $150-250 per pound by September 2026 as cultivators rushed to liquidate inventory before the effective date. Farmers who planted THCA-rich hemp varieties in spring 2026 expecting harvest in fall 2026 faced catastrophic losses, as the 0.3% total THC limit made their crops unsalable in Virginia.

Multi-State Operator Positioning

Licensed medical cannabis operators viewed the hemp restrictions as a competitive advantage. By reducing the availability of low-cost hemp alternatives, the law potentially drove consumers toward licensed dispensaries, despite higher prices. Virginia's five pharmaceutical processors reported 15-25% increases in patient registrations between August and October 2026, according to CCA data.

Several MSOs with operations in other states announced plans to enter Virginia's hemp retail market under the new licensing framework. Curaleaf, Trulieve, and Cresco Labs each filed VDACS license applications in August 2026, signaling intent to establish hemp retail footprints ahead of adult-use cannabis sales. These companies possessed compliance infrastructure, legal resources, and capital reserves that small independent retailers lacked, positioning them to capture market share during the transition period.

Investment and Capital Flows

Venture capital investment in Virginia hemp companies effectively ceased following HB 698's passage. Cannabis-focused investment firms redirected capital to states with clearer regulatory pathways and larger addressable markets. Virginia hemp startups that raised seed funding in 2023-2024 reported difficulty securing Series A rounds in 2025-2026, with investors citing regulatory uncertainty and market size concerns.

Conversely, investment in licensed cannabis operators increased. Green Leaf Medical announced a $35 million expansion of its Purcellville cultivation facility in September 2026, citing "improved market conditions and regulatory clarity." Columbia Care Virginia secured $20 million in debt financing in October 2026 for dispensary expansion.

Employment Effects

Industry groups estimated that 3,000-5,000 jobs in Virginia's hemp sector faced elimination or displacement due to the restrictions. Retail positions accounted for the majority of losses, with an estimated 2,000-3,000 budtenders, managers, and support staff affected by store closures. Manufacturing and processing jobs showed more resilience, as some companies pivoted to producing compliant products or serving out-of-state markets.

The Virginia Employment Commission reported that unemployment insurance claims from former hemp industry workers increased by approximately 1,200 between August and October 2026, concentrated in urban areas including Richmond, Virginia Beach, and Arlington.

What Experts Say

Legal scholars, public health researchers, and industry analysts offered sharply divergent assessments of Virginia's hemp restrictions, reflecting broader national debates over cannabis federalism and regulatory approaches.

Robert Mikos, a law professor at Vanderbilt University and cannabis federalism expert, described Virginia's approach as "legally defensible but economically questionable" in an August 2026 interview with the Richmond Times-Dispatch. Mikos noted that the 2018 Farm Bill's savings clause clearly preserved state authority to restrict hemp products, making federal preemption arguments unlikely to succeed. However, he questioned whether creating separate regulatory frameworks for hemp and cannabis made policy sense, suggesting that "Virginia is essentially recreating the same product categories under different legal regimes, which creates confusion and compliance costs without clear public health benefits."

Dr. Sharon Levy, director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital, supported Virginia's restrictions from a pediatric health perspective. In testimony to the Virginia General Assembly in February 2024, Levy stated that emergency department visits involving high-potency hemp edibles in adolescents had increased nationally, with symptoms including severe anxiety, psychosis, and respiratory depression. Levy emphasized that products marketed as "hemp" or "CBD" misled parents about intoxication risks, making age restrictions and potency limits appropriate public health measures.

Jonathan Miller, general counsel for the U.S. Hemp Roundtable, a national trade association, criticized Virginia's approach as "regulatory overreach that threatens the viability of the hemp industry Congress intended to create." Miller argued in a September 2026 policy brief that states should address specific harms—such as sales to minors or mislabeling—through targeted enforcement rather than broad restrictions that effectively prohibit products legal under federal law. He noted that Virginia's 2-milligram serving size limit had no scientific basis and appeared designed to advantage licensed cannabis operators rather than protect consumers.

Andrew Kline, a cannabis industry attorney with Perkins Coie, characterized Virginia's restrictions as part of a broader trend of states "closing the hemp loophole" created by the 2018 Farm Bill. Kline observed that at least 15 states enacted similar restrictions between 2024 and 2026, suggesting that the Farm Bill's definition of hemp based solely on delta-9 THC concentration was "a drafting oversight that states are now correcting." He predicted that Congress would eventually amend federal hemp law to address intoxicating derivatives, potentially preempting state variations.

Dr. Michelle Peace, a forensic toxicologist at Virginia Commonwealth University, provided technical analysis supporting the restrictions in expert testimony during the Virginia Hemp Coalition litigation. Peace explained that delta-8 THC and THCA produce intoxication and impairment comparable to delta-9 THC, with similar effects on driving ability and cognitive function. She noted that the lack of standardized dosing and quality control in unregulated hemp products created unpredictable intoxication levels, particularly dangerous for inexperienced users. Peace's research, published in the Journal of Analytical Toxicology in 2025, found that commercial delta-8 products varied in potency by up to 400% from labeled amounts.

Economic analysts at the Virginia Commonwealth University Center for Public Policy offered mixed assessments. A September 2026 report estimated that the restrictions would reduce state tax revenue by $8-12 million annually through lost sales tax collections, while potentially increasing future cannabis tax revenue by $15-25 million annually by channeling consumers toward the licensed market. The report concluded that the net fiscal impact depended heavily on the timeline for adult-use cannabis implementation and tax rates ultimately adopted.

What's Next

Virginia's hemp restrictions enter a critical implementation phase in late 2026 and 2027, with multiple decision points that will determine the long-term structure of the Commonwealth's cannabis marketplace.

Immediate Compliance Deadlines

VDACS established a 60-day grace period from August 15, 2026, during which the agency will issue warnings rather than citations for licensing violations, provided retailers demonstrate good-faith compliance efforts. This grace period expires October 14, 2026, after which full enforcement begins. Retailers must submit license applications, remove non-compliant products, and implement age verification systems by that date to avoid criminal penalties.

The agency scheduled compliance workshops in Richmond, Virginia Beach, Roanoke, and Fairfax in September and October 2026 to assist businesses with the transition. VDACS reported receiving approximately 600 license applications as of October 1, 2026—roughly half the number of retailers operating before the restrictions took effect, confirming industry predictions of significant market contraction.

Ongoing Litigation

The Virginia Hemp Coalition's lawsuit remains active despite the preliminary injunction denial. Trial is scheduled for March 2027 in the U.S. District Court for the Eastern District of Virginia. The coalition's attorneys indicated they will present expert testimony on the economic impact of the restrictions, constitutional law arguments, and evidence of alleged discriminatory enforcement.

If the coalition prevails at trial, the court could invalidate portions or all of HB 698, potentially reopening the market to previously restricted products. However, legal experts consider this outcome unlikely given Judge Trenga's detailed preliminary injunction opinion rejecting the coalition's core arguments. Appeals to the Fourth Circuit Court of Appeals and potentially the U.S. Supreme Court could extend litigation into 2028 or beyond.

Adult-Use Cannabis Implementation

Virginia's adult-use cannabis market, authorized by legislation passed in 2021, remains on track for retail sales to begin in 2027, pending final regulations from the CCA. The agency released draft rules in July 2026 proposing a licensing structure that would allow existing medical operators to convert to adult-use licenses while creating a separate application process for social equity applicants and new market entrants.

The interaction between hemp restrictions and adult-use cannabis rules represents a critical policy question. If adult-use regulations impose similar potency limits, packaging requirements, and age restrictions as the hemp law, the two markets would operate under parallel frameworks. However, if adult-use cannabis allows higher-potency products or more permissive marketing, it could create competitive advantages for licensed cannabis operators over hemp retailers.

Industry observers expect the CCA to finalize adult-use regulations by March 2027, with the first retail licenses issued by summer 2027. This timeline would create approximately one year during which the restricted hemp market operates before adult-use cannabis sales begin—a period likely to see continued market consolidation and business model evolution.

Potential Legislative Amendments

The 2027 Virginia General Assembly session, convening in January 2027, may consider amendments to HB 698 based on implementation experience. Potential changes include:

• Adjusting the 500-foot school buffer zone, which forced closure of retailers in dense urban areas
• Modifying potency limits based on public health data and market feedback
• Creating exemptions or reduced fees for small businesses and farmers
• Harmonizing hemp and adult-use cannabis regulations to reduce duplicative compliance
• Establishing a state-run testing laboratory to reduce costs for small manufacturers

Hemp industry advocates plan to lobby for these changes, though success depends on political dynamics and whether implementation reveals unintended consequences requiring correction.

National Implications

Virginia's approach to hemp restrictions is being closely watched by other states grappling with similar issues. At least eight states—including North Carolina, Tennessee, and Georgia—considered comparable legislation in 2026, with varying outcomes. Virginia's experience with implementation, litigation, and market effects will inform these ongoing state-level debates.

At the federal level, the U.S. Hemp Roundt